|Bid||542.21 x 800|
|Ask||566.57 x 800|
|Day's range||561.49 - 570.00|
|52-week range||305.63 - 579.00|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||106.14|
|Earnings date||28 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||544.10|
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
If you invest for the long term, you don't need to worry about short-term fluctuations in the market or what retail investors are betting on today. Two stocks that fall into that category are DexCom (NASDAQ: DXCM) and Microsoft (NASDAQ: MSFT). Luckily, DexCom and its continuous glucose monitoring devices can help patients manage the issue.